Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc., a Vancouver-based biopharmaceutical company specializing in DNA-damage response technologies for cancer treatment, has successfully closed subscriptions for $2 million worth of units. The company also expects to finalize the remaining $300,000 from their upsized private placement by week’s end, subject to TSX Venture Exchange approval.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
